Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Registration Number
- JPRN-jRCT2071220079
- Lead Sponsor
- ishikawa Kazuko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 111
Participants greater than or equal to (>=)18 years of age
- Have been diagnosed with warm autoimmune hemolytic anemia (wAIHA) for at least 3 months, and are currently receiving treatment for wAIHA or have previously received treatment for wAIHA (treatment-naive participants are not eligible)
- Participants must be able to understand and voluntarily provide written informed consent to participate in the study and comply with all study procedures
- Participants must not be pregnant or breastfeeding
- Participants must not have other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate
- Have been diagnosed with cold antibody autoimmune hemolytic anemia (AIHA), cold agglutinin syndrome, mixed type (that is, warm and cold) AIHA, or paroxysmal cold hemoglobinuria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method